Q1 2017 · —
Revenue$140.00K$140.00K no prior Q1 2016 on fileno prior Q4 2016 on file
Net Income-$5.88M-$5.88M N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$21.60-$21.60 N/M vs Q1 2016N/M vs Q4 2016
Operating Income-$7,599,000—
Operating Cash Flow-$6,979,000—
Margins · derived
Operating margin-5427.9%
Net margin-4197.1%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | $140.00K | — |
| Net Income | -$5.88M | -$5.91M |
| EPS Diluted | -$21.60 | -$21.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR